Evidence map›Paper›PMID 27613604›Full record

ArticleBMC cancer2016

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations.

Carole Grasso, Matthew Anaka, Oliver Hofmann, Ramakrishna Sompallae, Kate Broadley, Winston Hide, Michael V Berridge, Jonathan Cebon, Andreas Behren, Melanie J McConnell

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Suitability of CD133 as a Marker for Cancer Stem Cells in Melanoma.Asian Pacific journal of cancer prevention : APJCP · 2021
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 4 countries.

Carole GrassoMalaghan Institute of Medical Research, P.O. Box 7060, Wellington, 6242, New Zealand.
Matthew AnakaLudwig Institute for Cancer Research, Olivia Newton-John Cancer & Wellness Centre, Austin Hospital, Heidelberg, VIC, 3084, Australia.
Oliver HofmannHarvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA.
Ramakrishna SompallaeHarvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA.
Kate BroadleyMalaghan Institute of Medical Research, P.O. Box 7060, Wellington, 6242, New Zealand.
Winston HideHarvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA.
Michael V BerridgeMalaghan Institute of Medical Research, P.O. Box 7060, Wellington, 6242, New Zealand.
Jonathan CebonLudwig Institute for Cancer Research, Olivia Newton-John Cancer & Wellness Centre, Austin Hospital, Heidelberg, VIC, 3084, Australia.
Andreas BehrenLudwig Institute for Cancer Research, Olivia Newton-John Cancer & Wellness Centre, Austin Hospital, Heidelberg, VIC, 3084, Australia.
Melanie J McConnellMalaghan Institute of Medical Research, P.O. Box 7060, Wellington, 6242, New Zealand. Melanie.McConnell@vuw.ac.nz.
Malaghan Institute of Medical Research · NZAustin Hospital · AUHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe heterogeneity and tumourigenicity of metastatic melanoma is attributed to a cancer stem cell model, with CD133 considered to be a cancer stem cell marker in melanoma as well as other tumours, but its role has remained controversial.

methodsWe iteratively sorted CD133+ and CD133- cells from 3 metastatic melanoma cell lines, and observed tumourigenicity and phenotypic characteristics over 7 generations of serial xeno-transplantation in NOD/SCID mice.

resultsWe demonstrate that iterative sorting is required to make highly pure populations of CD133+ and CD133- cells from metastatic melanoma, and that these two populations have distinct characteristics not related to the cancer stem cell phenotype. In vitro, gene set enrichment analysis indicated CD133+ cells were related to a proliferative phenotype, whereas CD133- cells were of an invasive phenotype. However, in vivo, serial transplantation of CD133+ and CD133- tumours over 7 generations showed that both populations were equally able to initiate and propagate tumours. Despite this, both populations remained phenotypically distinct, with CD133- cells only able to express CD133 in vivo and not in vitro. Loss of CD133 from the surface of a CD133+ cell was observed in vitro and in vivo, however CD133- cells derived from CD133+ retained the CD133+ phenotype, even in the presence of signals from the tumour microenvironment.

conclusionWe show for the first time the necessity of iterative sorting to isolate pure marker-positive and marker-negative populations for comparative studies, and present evidence that despite CD133+ and CD133- cells being equally tumourigenic, they display distinct phenotypic differences, suggesting CD133 may define a distinct lineage in melanoma.

Indexed as

AC133 AntigenAnimalsCell LineageCell Line, TumorCell ProliferationCell SeparationHumansMelanomaMiceMice, Inbred NODMice, SCIDNeoplasm MetastasisNeoplasm TransplantationNeoplastic Stem CellsPhenotypeTumor MicroenvironmentAC133 AntigenPROM1 protein, human

Identifiers

PMID27613604
PMCPMC5017126
OpenAlexW2513361464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.